Evidence map›Paper›PMID 27473010›Full record

ArticlePediatric surgery international2016

Prophylactic efficacy of enteral miconazole administration for neonatal intestinal perforation and its potential mechanism.

Motofumi Torikai, Satoshi Ibara, Satoshi Ieiri, Takashi Hamada, Hiroyuki Noguchi, Kazunobu Sueyoshi, Takeo Fukuda, Kazuhiro Abeyama

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric surgery international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Motofumi TorikaiDepartment of Pediatric Surgery, Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan. motori@m.kufm.kagoshima-u.ac.jp.
Satoshi IbaraDepartment of Neonatology, Perinatal Medical Center, Kagoshima City Hospital, Kagoshima, Japan.
Satoshi IeiriDepartment of Pediatric Surgery, Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, 8-35-1, Sakuragaoka, Kagoshima, 890-8520, Japan.
Takashi HamadaDepartment of Preventive Medicine supported by Shin Nippon Biomedical Laboratories, Ltd. (SNBL), Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, Kagoshima, Japan.
Hiroyuki NoguchiDivision of Pediatric Surgery, Kagoshima City Hospital, Kagoshima, Japan.
Kazunobu SueyoshiDivision of Clinical Pathology, Kagoshima City Hospital, Kagoshima, Japan.
Takeo FukudaDepartment of Preventive Medicine supported by Shin Nippon Biomedical Laboratories, Ltd. (SNBL), Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, Kagoshima, Japan.
Kazuhiro AbeyamaDepartment of Preventive Medicine supported by Shin Nippon Biomedical Laboratories, Ltd. (SNBL), Research Field in Medical and Health Sciences, Medical and Dental Area, Research and Education Assembly, Kagoshima University, Kagoshima, Japan.
Kagoshima City Hospital · JPKagoshima University · JPShin Nippon Biomedical Laboratories (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIntestinal perforation (IP) is a fatal complication in extremely low birth weight infants (ELBWI). We started administrating enteral miconazole (MCZ) to ELBWI in 2002. Since then, the incidence of IP has significantly decreased. The aim of this study was to elucidate the prophylactic effect of MCZ for the treatment of neonatal IP, and to establish a new prophylactic concept for this disease.

methodsIn in vivo experiments, the effects of MCZ were examined histopathologically using a mouse model of intestinal ischemia. In in vitro experiments, the cytoprotective effect of MCZ against hypoxia was evaluated using Caco-2 intestinal cells, and its anti-inflammatory potential using a co-culture model of Caco-2 and HL60 cells.

resultsMCZ showed a tissue protective effect against intestinal ischemia. MCZ reduced high mobility group-box 1 (HMGB1) release in Caco-2 cells under hypoxic stress and attenuated the potential to activate co-cultured HL60 leukocytes with Caco-2 cells by suppressing interleukin-8 (IL-8).

conclusionMCZ may have preventive roles in the clinical management of IP in ELBWI by the suppression of IL-8 and HMGB-1.

Indexed as

AnimalsCaco-2 CellsCytochrome P-450 CYP2C9 InhibitorsDisease Models, AnimalHumansIntestinal PerforationIntestinesMaleMiceMice, Inbred BALB CMiconazoleTreatment OutcomeCytochrome P-450 CYP2C9 InhibitorsMiconazoleHMGB1IL-8Intestinal perforationsMiconazoleNecrotizing enterocolitisNewborn

Identifiers

PMID27473010
OpenAlexW2493324171

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.